Uterine Fibroids Drug Pipeline Analysis Report 2025

Uterine fibroids affect approximately 80% of the global female population. Around 1 in 3 or 4 women in their reproductive age are prone to get affected by the condition. More than 50% of the affected women are asymptomatic. Abnormal uterine bleeding is one of the most common symptoms exhibited in 64% of women with fibroids. The market is witnessing a surge in drug development and treatment alternatives. Major healthcare players and research institutions are investing in drug development, leading to several uterine fibroids drugs in the pipeline.

Report Coverage

The Uterine Fibroids Pipeline Report by the publisher gives comprehensive insights into Uterine Fibroids drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The uterine fibroids report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on Uterine Fibroids.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing uterine fibroids pipeline development activities are covered in this report.

Uterine Fibroids Drug Pipeline Outlook

Uterine fibroids (also known as leiomyomas or myomas) are small non-cancerous growths in the uterus. There are not many distinctive symptoms for uterine fibroids, however, painful periods with heavy menstrual bleeding, pelvic pain or pressure, pain during intercourse, and trouble in urination may occur in patients affected by the condition. These fibroids may vary in size or number. Fibroids are more common in women in their reproductive age and may shrink as they hit menopause. The presence of fibroids is commonly diagnosed through a routine pelvic exam. Ultrasounds, MRIs, hysterosonography, hysterosalpingography and hysteroscopy can also be used.

Treatment for uterine fibroids involves the administration of medicines, non-invasive procedures like MRI-guided focused ultrasound surgery (FUS), and minimally invasive procedures like uterine artery embolization, laparoscopic or robotic myomectomy. Uterine fibroids drugs are the most common initial treatment for the condition. Gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, selective progesterone receptor modulators (SPRMs), progestins, and anti-fibrinolytic agents are some of the drug classes used to manage the disease and reduce the size of fibroids.

Uterine Fibroids - Drug Pipeline Therapeutic Assessment

This section of the uterine fibroids pipeline report covers the analysis of uterine fibroid drugs based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The uterine fibroids therapeutic assessment report covers 50+ drug analyses based on drug classes:

• Gonadotropin-Releasing Hormone (GnRH) Agonists
• GnRH Antagonists
• Selective Progesterone Receptor Modulators (SPRMs)
• Progestins
• Combined Oral Contraceptives
• Anti-fibrinolytic Agents
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Aromatase Inhibitors

By Route of Administration

The uterine fibroids report insights cover 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Uterine Fibroids - Pipeline Assessment Segmentation, By Phases

The uterine fibroids report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials conducted, with over 80 drugs in the pipeline.

Uterine Fibroids - Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under uterine fibroids pipeline analysis include gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, combined oral contraceptives, selective progesterone receptor modulators (SPRMs), nonsteroidal anti-inflammatory drugs (NSAIDs), progestins, aromatase inhibitors and anti-fibrinolytic agents and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.

Uterine Fibroids Clinical Trials Assessment - Competitive Dynamics

The report for the Uterine Fibroids pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uterine fibroids clinical trials:

• Repros Therapeutics Inc.
• Myovant Sciences GmbH
• Bayer AG
• AbbVie Inc.
• Takeda Pharmaceutical Industries, Ltd
• Others

Uterine Fibroids - Emerging Drugs Profile

Letrozole

This drug is being evaluated for the treatment of uterine fibroid-related symptoms as a part of the PLUM Study, which is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial. It is under Phase 4 of the interventional study.

Proellex

Currently, under phase 2 of a multi-centre, parallel design, randomized study, this uterine fibroids drug candidate is under investigation to determine its safety and efficacy for premenopausal women with symptomatic uterine fibroids. Proellex ® (Telapristone Acetate), is developed by Allergan and is administered vaginally.

Progenta (CDB-4124)

Sponsored by Repros Therapeutics Inc., Progenta, a symptomatic uterine fibroids emerging drug, is currently under early-phase evaluation in women. The trial involves administering 3 doses of Progenta (12.5, 25, 50 mg) against the placebo.

Reasons To Buy This Report

The Uterine Fibroids Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for uterine fibroids. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Uterine Fibroids - Pipeline Assessment Report

• What is the current landscape of uterine fibroids pipeline drugs?
• Which companies/institutions are developing uterine fibroids drug candidates?
• How many phase II drugs are currently present in uterine fibroids pipeline drugs?
• Which company is leading the uterine fibroids pipeline development activities?
• What is the current uterine fibroids therapeutic assessment?
• What are the opportunities and challenges present in the uterine fibroids drug pipeline landscape?
• What is the efficacy and safety profile of uterine fibroids pipeline drugs?
• Which companies/institutions are involved in uterine fibroids collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in uterine fibroids?

This product will be delivered within 3-5 business days.